Cellectar Biosciences Inc (NASDAQ:CLRB) investors are overwhelmingly excited this morning after the biopharmaceutical company provided a positive update on its Phase I clinical study …
Cellectar Biosciences Inc (NASDAQ:CLRB) announces the advance online publication of an article in Nature Reviews Clinical Oncology. In addition, the company anticipates an …
Cellectar Biosciences Inc (NASDAQ:CLRB) investors cheer the news that the United States Patent and Trademark Office has granted patent number 9,550,002, which covers method …
